Dulaglutide Peptide: Trulicity, AWARD and REWIND Evidence
Dulaglutide peptide guide covering the Trulicity GLP-1 Fc-fusion mechanism, AWARD program glycemic data, REWIND cardiovascular outcomes, label doses and safety limits.
Dulaglutide is a peptide-based prescription medicine with a much stronger evidence base than most research-market GLP-1 compounds. It is a once-weekly glucagon-like peptide-1 receptor agonist sold as Trulicity, and it was approved by the FDA in 2014 for type 2 diabetes. Unlike many short peptides discussed online, dulaglutide is an engineered Fc-fusion molecule with large randomized trials, a cardiovascular outcomes study and a detailed prescribing label.
The defining structural detail is the Fc fusion. Dulaglutide links two modified GLP-1 analog chains to a fragment of human immunoglobulin G4. That design resists the rapid enzymatic breakdown that limits native GLP-1, which is why a single subcutaneous dose can act across a full week. This places it in the same broad family as semaglutide, tirzepatide and liraglutide, but with its own molecule, label and dose schedule.
This guide is educational and not medical advice. Dulaglutide is a prescription medicine with a boxed warning. It should be started, monitored, changed or stopped only through qualified medical care.
Dulaglutide At A Glance
| Question | Evidence-aware answer |
|---|---|
| What is it? | A once-weekly GLP-1 receptor agonist peptide fused to an immunoglobulin Fc fragment. |
| Brand name | Trulicity, developed by Eli Lilly. |
| Main effect | Glucose-dependent insulin release, glucagon suppression, slower gastric emptying and reduced appetite. |
| Approved uses | Type 2 diabetes glycemic control and cardiovascular event reduction per the FDA label. |
| Route and schedule | Subcutaneous injection, once weekly, via a prefilled single-dose pen. |
| Evidence type | The AWARD phase 3 program, the REWIND cardiovascular outcomes trial and the FDA prescribing label. |
| Main safety frame | Boxed thyroid C-cell tumor warning, plus gastrointestinal and pancreatitis cautions. |
How A GLP-1 Receptor Agonist Works
Native GLP-1 is an incretin hormone released from the gut after eating. It binds the GLP-1 receptor and triggers several coordinated effects: it boosts insulin secretion when blood glucose is elevated, lowers glucagon, slows how fast the stomach empties and signals satiety in the brain. The catch is that native GLP-1 is degraded within minutes by the enzyme DPP-4, so it cannot be used as a practical once-weekly drug on its own.
Dulaglutide solves that problem with engineering. Its GLP-1 analog regions carry amino acid substitutions that resist DPP-4 cleavage, and the attached Fc fragment slows renal clearance and extends circulation time. The result is a large molecule with an elimination half-life of roughly five days, according to the Trulicity prescribing information. Steady-state plasma levels are reached in about two to four weeks of once-weekly dosing.
Because insulin release is glucose-dependent, the risk of dulaglutide causing low blood sugar on its own is low. Hypoglycemia risk rises mainly when it is combined with insulin or sulfonylureas. For broader background, see what GLP-1 is and the overview of GLP-1 receptor agonists.
Approval Status And Indications
Dulaglutide is fully FDA-approved, which separates it sharply from research-only peptides. The Trulicity label indicates it as an adjunct to diet and exercise to improve glycemic control in adults and in pediatric patients 10 years and older with type 2 diabetes. It is also indicated to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors.
The label is equally clear about what dulaglutide is not. It is not indicated for type 1 diabetes, not for diabetic ketoacidosis and not approved as a weight-loss medication. Weight reduction is reported as a secondary effect in diabetes trials, not as a standalone obesity indication. That distinction matters when comparing it against drugs studied specifically for weight loss.
AWARD Program Evidence
Dulaglutide's efficacy rests on the AWARD phase 3 clinical trial program, a series of randomized studies that tested it against placebo and active comparators across different type 2 diabetes settings. These trials supported the original approval of the 0.75 mg and 1.5 mg doses and demonstrated meaningful HbA1c reductions.
The label later expanded to higher doses based on AWARD-11, a randomized trial in metformin-treated patients. AWARD-11 compared dulaglutide 3.0 mg and 4.5 mg against 1.5 mg and reported dose-related improvements: at 36 weeks the published results described additional HbA1c lowering and additional weight loss with the higher doses, with mean reductions in HbA1c up to roughly 1.9 percent and weight loss up to about 5 kg in the higher-dose groups. The safety profile across doses was broadly similar.
The honest framing is that these are robust, peer-reviewed trials in people with type 2 diabetes. They establish glycemic efficacy and a consistent dose relationship, but they do not make dulaglutide an approved obesity therapy, and the weight effects are smaller than those seen with some newer agents in the GLP-1 drugs list.
REWIND Cardiovascular Outcomes
The REWIND trial is the cardiovascular centerpiece of the dulaglutide evidence. Published in The Lancet in 2019, it was a double-blind, randomized, placebo-controlled trial of 9,901 participants with type 2 diabetes, followed for a median of about 5.4 years. Notably, only around 31 percent of participants had established cardiovascular disease at baseline, so the trial leaned toward a primary-prevention population with risk factors.
The primary composite outcome of cardiovascular death, nonfatal myocardial infarction or nonfatal stroke occurred in 12.0 percent of the dulaglutide group versus 13.4 percent of the placebo group, a hazard ratio of 0.88. An exploratory analysis also reported a reduction in stroke, driven by ischemic stroke. These findings supported the cardiovascular indication on the label.
REWIND is a genuine outcomes trial, not a surrogate-marker study, which is what makes it credible. The limits are worth naming: the absolute risk reduction was modest, the population had relatively low baseline HbA1c, and the benefit applies to the studied diabetes population rather than to healthy individuals using the drug off-label.
Safety Limits
Dulaglutide safety follows from its mechanism and from the FDA label. The most prominent item is a boxed warning.
| Safety issue | Why it matters |
|---|---|
| Thyroid C-cell tumors (boxed warning) | Rodent studies showed thyroid C-cell tumors; the label contraindicates use with personal or family history of medullary thyroid carcinoma or MEN 2. |
| Pancreatitis | Acute pancreatitis has been reported; the label advises stopping the drug if it is suspected. |
| Gastrointestinal effects | Nausea, vomiting, diarrhea and abdominal pain are the most common adverse effects and can cause dehydration. |
| Hypoglycemia | Low risk alone, but meaningfully increased when combined with insulin or sulfonylureas. |
| Acute kidney injury | Dehydration from GI effects can worsen renal function, especially in those with kidney impairment. |
| Diabetic retinopathy | Rapid glycemic improvement can be associated with retinopathy complications in some patients. |
| Hypersensitivity | Serious reactions including anaphylaxis and angioedema have been reported. |
| Gallbladder disease | Cholelithiasis and gallbladder events are recognized with GLP-1 therapy. |
These overlap heavily with the broader class. For a fuller picture, see GLP-1 side effects. The boxed thyroid warning in particular is a reason dulaglutide should never be treated as a casual self-administered peptide.
How To Evaluate A Dulaglutide Claim
Ask five questions before trusting any dulaglutide claim.
First, is the source talking about the approved Trulicity product or unverified research-market material? Only the licensed product carries the trial and label evidence described here.
Second, is the claim about diabetes or weight loss? Dulaglutide has strong diabetes and cardiovascular data but is not an approved obesity drug, so weight-loss marketing is using off-label framing.
Third, does the source acknowledge the boxed thyroid warning and the contraindications? A page that omits them is incomplete.
Fourth, is it comparing dulaglutide fairly against alternatives? Agents such as semaglutide and tirzepatide have produced larger weight effects in dedicated trials, and the dual-hormone amylin analog pramlintide works through a different pathway entirely.
Fifth, does it respect pharmacology? The long action comes from the Fc fusion and roughly five-day half-life; for the general concept see peptide half-life explained. Anyone promising a different schedule is not describing the labeled product.
Bottom Line
Dulaglutide is a real, FDA-approved peptide medicine with a deep evidence base. Its Fc-fusion design gives it once-weekly dosing, the AWARD program established glycemic efficacy across a 0.75 to 4.5 mg dose range, and the REWIND trial demonstrated a reduction in major cardiovascular events in people with type 2 diabetes. Those are meaningful, label-backed achievements that most marketed peptides cannot match.
The same evidence defines its limits. Dulaglutide is approved for diabetes and cardiovascular risk reduction, not for general weight loss, and it carries a boxed thyroid C-cell tumor warning along with pancreatitis, gastrointestinal and renal cautions. The dose ranges cited here come from the FDA label and trials and are descriptive, not recommendations. Dulaglutide belongs to the same family as other peptides for weight loss discussion, but it is a prescription drug whose safe use depends on the label, the indication and a clinician.
References
DailyMed. Trulicity (dulaglutide) injection prescribing information.
FDA. TRULICITY (dulaglutide) Highlights of Prescribing Information.
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet, 2019.
Gerstein HC, et al. The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial. Lancet Diabetes & Endocrinology, 2019.
Frias JP, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes (AWARD-11). Diabetes Care, 2021.
Bonora BM, et al. Effect of dulaglutide 3.0 and 4.5 mg on weight in patients with type 2 diabetes: exploratory analyses of AWARD-11. Diabetes, Obesity and Metabolism, 2021.
Smith LL, et al. Dulaglutide (Trulicity): The Third Once-Weekly GLP-1 Agonist. P&T, 2016.
ClinicalTrials.gov. Researching Cardiovascular Events With a Weekly Incretin in Diabetes (REWIND).